Table 1.
Responses to BCR inhibitor treatment in different B cell malignancies.
| Patient Population | Target | Drug | ORR | CR Rate | PFS | Ref. |
|---|---|---|---|---|---|---|
| CLL/SLL (R/R *) | BTK | Ibrutinib | 71% | 2% | 88% at 6 months | [187] |
| CLL/SLL (R/R) | BTK | Ibrutinib | 94% | 9% | 76% at 30 months | [188] |
| CLL/SLL (R/R) | BTK | Ibrutinib | 69% | 13% | n/a | [189] |
| CLL (R/R) | BTK | Acalabrutinib | 95% | 0 | 90% at 16 months | [190] |
| CLL (R/R) | BTK | Tirabrutinib | 96% | n/a | median 29 months | [191] |
| CLL (R/R) | PI3Kδ | Idelalisib | 72% | 0 | median 15.8 months | [192] |
| SLL (R/R) | PI3Kδ | Idelalisib | 61% | n/a | n/a | [193] |
| CLL/SLL (R/R) | PI3Kα/δ | Duvelisib | 74% | 0.6% | median 13.3 months | [194] |
| SLL (R/R) | PI3Kα/δ | Copanlisib | 75% | 0 | n/a | [195] |
| CLL/SLL (R/R) | SYK | Fostamatinib | 55% | 0 | median 6.4 months | [196] |
| CLL (R/R) | SYK | Entospletinib | 61% | 0 | median 13.8 months | [197] |
| CLL (R/R) | SYK | Entospletinib | 33% | 0 | median 5.6 months | [198] |
| CLL/SLL (R/R) | SYK/JAK | Cerdulatinib | 38% | 0 | n/a | [199] |
| CLL/SLL (R/R) | mTOR | Everolimus | 18% | 0 | median 5.1 months | [200] |
| CLL/SLL (R/R) | mTOR | Everolimus | 19% | 0 | n/a | [201] |
| CLL/SLL (R/R) | SFKs | Dasatinib | 60% | 13% | median 7.5 months | [202] |
| CLL (TN*) | BTK | Ibrutinib | 85% | 26% | 90% at 18 months | [188] |
| CLL (TN*) | BTK | Ibrutinib | 86% | 4% | not reached | [203] |
| ABC-DLBCL (R/R) | BTK | Ibrutinib | 37% | 10% | median 2 months | [105] |
| GCB-DLBCL (R/R) | BTK | Ibrutinib | 5% | 0 | median 1.3 months | [105] |
| DLBCL (R/R) | BTK | Tirabrutinib | 35% | 9% | median 1.7 months | [191] |
| DLBCL (R/R) | PI3Kδ | Idelalisib | 0% | 0% | 0 | [18] |
| ABC-DLBCL (R/R) | PI3Kα/δ | Copanlisib | 32% | 21% | median 4.3 months | [19] |
| GCB-DLBCL (R/R) | PI3Kα/δ | Copanlisib | 13% | 3% | median 6.0 months | [19] |
| DLBCL (R/R) | SYK | Fostamatinib | 22% | 6% | median 2.7 months | [196] |
| DLBCL (R/R) | SYK | Entospletinib | 0 | 0 | median 1.5 months | [204] |
| DLBCL (R/R) | SYK/JAK | Cerdulatinib | 6% | 0 | n/a | [199] |
| FL (R/R) | BTK | Ibrutinib | 38% | 19% | n/a | [189] |
| FL (R/R) | BTK | Ibrutinib | 38% | 13% | median 14 months | [205] |
| FL (R/R) | PI3Kδ | Idelalisib | 54% | n/a | n/a | [193] |
| FL (R/R) | PI3Kδ | Idelalisib | 57% | 6% | median 11 months | [206] |
| FL (R/R) | PI3Kα/δ | Duvelisib | 42% | 1% | n/a | [207] |
| FL (R/R) | PI3Kα/δ | Copanlisib | 59% | 14% | median 11.2 months | [195] |
| FL (R/R) | SYK | Fostamatinib | 10% | 0 | median 4.6 months | [196] |
| FL (R/R) | SYK | Entospletinib | 17% | 0 | median 5.7 months | [208] |
| FL (R/R) | SYK/JAK | Cerdulatinib | 31% | 15% | n/a | [199] |
| FL (R/R) | mTOR | Everolimus | 61% | 9% | n/a | [201] |
| MCL (R/R) | BTK | Ibrutinib | 68% | 21% | median 13.9 months | [209] |
| MCL (R/R) | BTK | Ibrutinib | 78% | 33% | n/a | [189] |
| MCL (R/R) | BTK | Tirabrutinib | 92% | 46% | median 11 months | [191] |
| MCL (R/R) | PI3Kδ | Idelalisib | 40% | 5% | median 3.7 months | [210] |
| MCL (R/R) | PI3Kα/δ | Copanlisib | 64% | 18% | n/a | [211] |
| MCL (R/R) | SYK | Fostamatinib | 11% | 0 | median 3.8 months | [196] |
| MCL (R/R) | SYK | Entospletinib | 18% | 0 | median 5.6 months | [208] |
| MCL (R/R) | SYK/JAK | Cerdulatinib | 0 | 0 | n/a | [199] |
| MCL (R/R) | mTOR | Temsirolimus | 38% | 3% | median 6.5 months | [212] |
| MCL (R/R) | mTOR | Temsirolimus | 22% | 0 | median 4.8 months | [213] |
| MCL (R/R) | mTOR | Temsirolimus | 40% | n/a | median 6.2 months | [214] |
| MZL (R/R) | BTK | Ibrutinib | 48% | 3% | median 14.2 months | [215] |
| MZL (R/R) | PI3Kδ | Idelalisib | 47% | n/a | n/a | [193] |
| MZL (R/R) | PI3Kα/δ | Duvelisib | 39% | 6% | n/a | [207] |
| MZL (R/R) | PI3Kα/δ | Copanlisib | 70% | 9% | n/a | [195] |
| MZL (R/R) | SYK | Entospletinib | 12% | 0 | median 5.5 months | [208] |
| WM (TN) | BTK | Ibrutinib | 91% | 0 | 69% at 24 months | [199] |
| WM (R/R) | BTK | Ibrutinib | 75% | 0 | / | [189] |
| WM (R/R) | BTK | Tirabrutinib | 94% | 0 | not reached | [216] |
| WM (TN) | BTK | Tirabrutinib | 100% | 0 | not reached | [216] |
| WM/LPL(R/R) | PI3Kδ | Idelalisib | 80% | n/a | n/a | [193] |
| WM/LPL(R/R) | SYK | Entospletinib | 35% | 0 | median 10.9 months | [208] |
| WM/LPL(R/R) | PI3Kα/δ | Copanlisib | 17% | 0 | n/a | [195] |
* R/R, relapsed/refractory; TN, treatment naive; SLL, small lymphocytic lymphoma; n/a, not available.